Related Experiment Video
Updated: May 11, 2026
Gene-environment Interaction Models to Unmask Susceptibility Mechanisms in Parkinson's Disease
Published on: January 7, 2014
The effects of 8-OH-DPAT on neuroinflammation after sarin exposure in mice
Teresa L Garrett1, Kaushal Joshi, Christine M Rapp
1Pharmacology & Toxicology, Boonshoft School of Medicine, Wright State University, 3640 Colonel Glenn Highway, Dayton, OH 45435, USA.
Abstract:
Poisoning by organophosphate nerve agents can induce seizures which rapidly become refractory to treatment and result in brain damage. Current therapies have only a narrow time frame for effective administration after poisoning. 5-HT1A agonists were tested for efficacy in mice against a seizure-producing combination of the carboxylesterase inhibitor 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide (CBDP) and sarin, producing an LD20-40. Administration of the 5-HT1A agonist, 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) decreased glial fibrillary acidic protein (GFAP) staining in mice when administered 1min after CBDP and sarin while other 5-HT1A agonists buspirone and S-14506 were not effective. The reduction in GFAP staining by 8-OH-DPAT remained significant when a single dose was administered 2h after the toxic challenge. In addition, 8-OH-DPAT reversed the increase in the inflammatory factor IL-1β in the dentate gyrus and amygdala but did not reduce positive TUNEL staining in the dentate gyrus. Due to the failure of the two other agonists to provide protection, the 5-HT1A antagonist WAY-100635 was tested. WAY-100635 was found to neither reverse the neuroprotective effects of 8-OH-DPAT nor worsen the damage when given alone, making a role for this receptor unlikely. The neuroprotective effects of 8-OH-DPAT appear to lie within its secondary pharmacology.
Insights
The 5-HT1A agonist 8-OH-DPAT shows neuroprotective effects against organophosphate nerve agent poisoning in mice. It reduces brain inflammation and damage, even when administered hours after exposure.
Area of Science:
- Neuroscience
- Pharmacology
- Toxicology
Background:
- Organophosphate nerve agents cause seizures and brain damage, with limited treatment windows.
- Current therapies for nerve agent poisoning are time-sensitive and may be insufficient.
Purpose of the Study:
- To investigate the efficacy of 5-HT1A agonists in protecting against nerve agent-induced seizures and brain damage.
- To explore the neuroprotective mechanisms of 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) in a mouse model.
Main Methods:
- Mice were exposed to a seizure-inducing combination of 2-(o-cresyl)-4H-1:3:2-benzodioxaphosphorin-2-oxide (CBDP) and sarin.
- Administration of 5-HT1A agonists (8-OH-DPAT, buspirone, S-14506) and antagonist (WAY-100635) at various time points.
- Assessment of neuroprotection via glial fibrillary acidic protein (GFAP) staining, IL-1β levels, and TUNEL staining.
Main Results:
- 8-OH-DPAT significantly decreased GFAP staining when given 1 minute or 2 hours post-exposure.
- 8-OH-DPAT reversed increased IL-1β levels in the dentate gyrus and amygdala.
- Buspirone and S-14506 did not provide protection; WAY-100635 did not alter 8-OH-DPAT's effects.
Conclusions:
- 8-OH-DPAT exhibits significant neuroprotective properties against organophosphate nerve agent toxicity in mice.
- The protective effects of 8-OH-DPAT may stem from its secondary pharmacological actions rather than direct 5-HT1A agonism.
- Further research into 8-OH-DPAT's secondary pharmacology is warranted for potential therapeutic development.
![PET Imaging of Neuroinflammation Using [11C]DPA-713 in a Mouse Model of Ischemic Stroke](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F57243.jpg&w=3840&q=50)